HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected H2 2025 NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage ...

NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFERRules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:HOOKIPA Pharma Inc.(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c) Name of offeror/offeree in relat ...

NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg ...

Potential Combination Update - Poolbeg Pharma and HOOKIPA Pharma are in discussions regarding a potential combination, with significant shareholder Gilead Sciences indicating its intention to vote in favor of the deal if a formal offer is made [2][3] - Gilead owns 1,875,947 HOOKIPA common shares, representing 19.4% of HOOKIPA's existing issued share capital [3] Fundraise Details - HOOKIPA has amended the details of its planned Fundraise, now expecting to undertake a 100% primary private placement fundraise of approximately $30 million+, up from the previously stated $30 million [4] - Oppenheimer & Co Inc has been engaged as the placement agent for the private placement fundraise [5] Advisors and Contacts - Poolbeg has engaged Cavendish Capital Markets, Canaccord Genuity, Shore Capital, and J&E Davy as financial advisers and brokers [6][7][14][15] - HOOKIPA has engaged Moelis & Company as its financial adviser [8][16] - Contact details for key executives and investor relations teams at both companies are provided [6][7]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 January 2025 HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment    NEW YORK and VIENNA, Austria, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The following amendment has been made to the ‘Rule 2.9 Information’ disclosed by HOOKIPA in the Rule 2.4 announcement made on 2 January 2025 regarding the poten ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (Mark One) For the transition period from ________________ to ________________. Commission File Number: 001-38869 HOOKIPA PHARMA INC. (Exact Name of Registrant as Specified in its ...

Exhibit 99.1 HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head ...

NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6th Annual RAS-Targeted Drug Development Summit being held in Boston, Massachusetts from September ...

HOOKIPA Pharma Inc. (HOOK) closed the last trading session at $5.23, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $37.80 indicates a 622.8% upside potential. The average comprises five short-term price targets ranging from a low of $15 to a high of $60, with a standard deviation of $18.42. While the lowest estimate indicates an increase of 186.8% from the current pr ...

NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as NonExecutive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief ...